ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01830322
Recruitment Status : Withdrawn
First Posted : April 12, 2013
Last Update Posted : August 14, 2013
Sponsor:
Information provided by (Responsible Party):
Rafael Pharmaceuticals Inc.

Brief Summary:
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with metastatic pancreatic cancer. The primary outcome measure is Overall Survival (OS). The secondary outcome measures are: changes in CA 19-9, Quality of Life (QOL), Progression-Free Survival (PFS), and safety.

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Adenocarcinoma Drug: CPI-613 Drug: Gemcitabine Drug: Any non-gemcitabine chemotherapies or best supportive care Phase 2

Detailed Description:

Data from dose-escalated Phase I trials indicate that CPI-613 is safe and effective against metastatic pancreatic cancer (Lee et al. 2012; Retter et al. 2012). Accordingly, this Phase II trial is conducted to assess the safety and efficacy of CPI-613 in patients with metastatic pancreatic cancer.

Primary Outcome Measure:

- Overall Survival (OS)

Secondary Outcome Measures:

  • Changes in CA 19-9
  • Quality of Life (QOL) assessment
  • Progression-Free Survival (PFS)
  • Safety

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer
Study Start Date : January 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CPI-613 Alone
This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
Drug: CPI-613
CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
Other Names:
  • 6,8-bis-benzylsulfanyloctanoic acid
  • 6,8-bis(benzylthio)octanoic acid
  • 6,8-bis-benzylsulfonyloctanoic acid
  • Bylantra

Active Comparator: Any non-gemcitabine chemotherapies or best supportive care
This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
Drug: Any non-gemcitabine chemotherapies or best supportive care
Experimental: Gemcitabine + CPI-613 in combination
This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
Drug: CPI-613
CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
Other Names:
  • 6,8-bis-benzylsulfanyloctanoic acid
  • 6,8-bis(benzylthio)octanoic acid
  • 6,8-bis-benzylsulfonyloctanoic acid
  • Bylantra

Drug: Gemcitabine
Other Names:
  • 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (beta-isomer)
  • 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on
  • Gemcitabine HCl
  • Gemzar

Experimental: Gemcitabine alone or in combination with therapeutic agent(s)
This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
Drug: Gemcitabine
Other Names:
  • 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (beta-isomer)
  • 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on
  • Gemcitabine HCl
  • Gemzar




Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Monitored until participants pass away, for an expected average of 6 months. ]

Secondary Outcome Measures :
  1. Changes in CA 19-9 [ Time Frame: Monitored within 2-weeks before treatment, and every 3-cycles (months) during treatment ]
    CA 19-9 is monitored through blood work ≤2 weeks before treatment and after every third cycle (12 weeks) of treatment while on-study. CA 19-9 is a pancreatic tumor biomarker and a decline in CA 19-9 during and after therapy may be a marker of treatment efficacy.

  2. Quality of Life (QOL) [ Time Frame: Monitored before, during, and 1-week after treatment with CPI-613, for an expected average of 20 weeks. ]
    QOL will be assessed as described by Aaronson NK, et al. 1993. It assesses how the various treatments and the disease affect the daily living abilities of the patient.

  3. Progression-Free Survival (PFS) [ Time Frame: Monitored during treatment with CPI-613 and until participants passed away, which will be an expected average of 6 months. ]
  4. Safety [ Time Frame: Monitored just before study treatment, and during study treatment at the end of every 4-week treatment cycle, for an expected average of 20 weeks. ]
    Safety assessment will be based on clinical signs, vital signs, blood work, adverse events (AEs), serious adverse events (SAEs), etc.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically and cytologically confirmed, measurable metastatic pancreatic adenocarcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status being 0-2
  • Expected survival >2 months
  • 18 years of age or older of both genders
  • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation. (Note: Pregnant patients are excluded because the effects of CPI-613 on a fetus are unknown.)
  • Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
  • At least 2 weeks must have elapsed from any prior surgery or hormonal therapy. Must have fully recovered from the acute toxicities of any prior treatment with any anti-cancer drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). Patients with persisting, stable chronic toxicities from prior treatment ≤Grade 1 are eligible, but must be documented as such.
  • Laboratory values ≤2 weeks must be:

    • Adequate hematologic (white blood cell [WBC] ≥3500 cells/mm3 or ≥3.5 bil/L; platelet count ≥150,000 cells/mm3 or ≥150 bil/L; absolute neutrophil count [ANC] ≥1500 cells/mm3 or ≥1.5 bil/L; and hemoglobin (Hgb) ≥9 g/dL or ≥90 g/L).
    • Adequate hepatic function (aspartate aminotransferase [AST/SGOT] ≤3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] ≤3x UNL (≤5x UNL if liver metastases present), bilirubin ≤1.5x UNL).
    • Adequate renal function (serum creatinine ≤2.0 mg/dL or 177 μmol/L, and blood urea nitrogen [BUN] ≤25 mg/dL).
    • Adequate coagulation ("International Normalized Ratio or INR must be <1.5"), unless treated with anticoagulants.
  • No evidence of active infection and no serious infection within the past month; no systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment.
  • Consent to participating the study by signed informed consent form

Exclusion Criteria:

  • Serious medical illness that would potentially increase patients' risk for toxicity
  • Any active uncontrolled bleeding or patients with a bleeding diathesis (e.g., active peptic ulcer disease)
  • Patients with active central nervous system (CNS) or epidural tumor
  • Lactating females (Note: Lactating females are excluded because the effects of CPI-613 on a nursing child are unknown)
  • Life expectancy less than 2 months
  • Unwilling or unable to follow protocol requirements
  • Dyspnea with minimal to moderate exertion, or patients with pleural, pericardial, or peritoneal effusions
  • Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction, arrhythmias requiring medication, or symptomatic congestive heart failure. Also patients with a history of myocardial infarction that is <1 year prior to registration, or patients with previous congestive heart failure (<1 year prior to registration) requiring pharmacologic support or with Left Ventricular Ejection Fraction <50%).
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated exhibition of a QTc interval >470 ms.); a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Requirement for immediate palliative treatment of any kind including surgery
  • Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01830322


Locations
United States, New York
Eastchester Center for Cancer Care
Bronx, New York, United States, 10469
United States, Texas
Temple Vasicek Cancer Treatment Center
Temple, Texas, United States, 76508
Sponsors and Collaborators
Rafael Pharmaceuticals Inc.
Investigators
Study Chair: King C Lee, Ph.D. Rafael Pharmaceuticals Inc.

Responsible Party: Rafael Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT01830322     History of Changes
Other Study ID Numbers: CL-CPI-613-024
First Posted: April 12, 2013    Key Record Dates
Last Update Posted: August 14, 2013
Last Verified: August 2013

Keywords provided by Rafael Pharmaceuticals Inc.:
metastatic
pancreatic
adenocarcinoma
cancer

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs